Login to Your Account



ImClone Opts Out Of UCB Deal To Develop CDP-791

By Randall Osborne


Wednesday, February 7, 2007
By backing out of development deal with UCB SA for the cancer drug CDP-791, ImClone Systems Inc. gains time and resources to work on its own blocker of vascular endothelial growth factor receptor-2, slated to finish Phase I trials in the first half of this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription